Therapeuticsmd, INC 10-Q quarterly reports

TherapeuticsMD, Inc. transitioned to a pharmaceutical royalty company, reporting increased license revenue and net income for the first quarter of 2026, while navigating ongoing legal disputes.

TherapeuticsMD reported a net income of $152,000 for Q3 2025 and $50,000 for the first nine months, a significant improvement from prior year losses, despite ongoing legal disputes and a 'going concern' warning.

TherapeuticsMD, a pharmaceutical royalty company, reported a significant increase in Q2 2025 license revenue and a return to net income from continuing operations, despite ongoing legal disputes and going concern doubts.

TherapeuticsMD, now a royalty-based pharmaceutical company, reports increased license revenue for Q1 2025 but faces a lawsuit with Mayne Pharma and going concern uncertainties.

TherapeuticsMD's third quarter 2024 results show increased license revenue and reduced operating expenses as the company continues its transition to a pharmaceutical royalty business.

TherapeuticsMD's second quarter results show a net loss of $1.09 million as the company continues its transition to a pharmaceutical royalty business.

TherapeuticsMD's first quarter 2024 results reflect its transition to a pharmaceutical royalty company, with a net loss of $734 thousand and a decrease in operating expenses.